BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 29764230)

  • 1. The modern role of antipsychotics for the treatment of agitation and psychosis in Alzheimer's disease.
    Creese B; Da Silva MV; Johar I; Ballard C
    Expert Rev Neurother; 2018 Jun; 18(6):461-467. PubMed ID: 29764230
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease.
    Ballard C; Waite J
    Cochrane Database Syst Rev; 2006 Jan; (1):CD003476. PubMed ID: 16437455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A markov model of the cost effectiveness of olanzapine treatment for agitation and psychosis in Alzheimer's disease.
    Kirbach S; Simpson K; Nietert PJ; Mintzer J
    Clin Drug Investig; 2008; 28(5):291-303. PubMed ID: 18407715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of agitation, aggression, and psychosis associated with dementia: a pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidone.
    De Deyn PP; Katz IR; Brodaty H; Lyons B; Greenspan A; Burns A
    Clin Neurol Neurosurg; 2005 Oct; 107(6):497-508. PubMed ID: 15922506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antipsychotic treatment of psychosis and agitation in the elderly.
    Daniel DG
    J Clin Psychiatry; 2000; 61 Suppl 14():49-52. PubMed ID: 11154017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progresses in treating agitation: a major clinical challenge in Alzheimer's disease.
    Panza F; Solfrizzi V; Seripa D; Imbimbo BP; Santamato A; Lozupone M; Prete C; Greco A; Pilotto A; Logroscino G
    Expert Opin Pharmacother; 2015; 16(17):2581-8. PubMed ID: 26389682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aripiprazole in the treatment of Alzheimer's disease.
    De Deyn PP; Drenth AF; Kremer BP; Oude Voshaar RC; Van Dam D
    Expert Opin Pharmacother; 2013 Mar; 14(4):459-74. PubMed ID: 23350964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atypical antipsychotics for the treatment of dementia-related behaviors: an update.
    Daiello LA
    Med Health R I; 2007 Jun; 90(6):191-4. PubMed ID: 17633594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Longterm treatment with Risperidone in Alzheimer's disease? No justification for more "drug deaths" in nursing homes!].
    Förstl H
    Dtsch Med Wochenschr; 2013 Jan; 138(1-2):16. PubMed ID: 23250689
    [No Abstract]   [Full Text] [Related]  

  • 10. Use of aripiprazole for psychosis and agitation in dementia.
    Laks J; Miotto R; Marinho V; Engelhardt E
    Int Psychogeriatr; 2006 Jun; 18(2):335-40. PubMed ID: 16255839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New antipsychotic drugs for the treatment of agitation and psychosis in Alzheimer's disease: focus on brexpiprazole and pimavanserin.
    Caraci F; Santagati M; Caruso G; Cannavò D; Leggio GM; Salomone S; Drago F
    F1000Res; 2020; 9():. PubMed ID: 32695312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Pipelines for Alzheimer's Disease Psychosis and Agitation.
    Oguma T; Jino K
    Chem Pharm Bull (Tokyo); 2024; 72(7):610-617. PubMed ID: 38945937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological treatment of psychosis and agitation in elderly patients with dementia: four decades of experience.
    Kindermann SS; Dolder CR; Bailey A; Katz IR; Jeste DV
    Drugs Aging; 2002; 19(4):257-76. PubMed ID: 12038878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The long-term effects of conventional and atypical antipsychotics in patients with probable Alzheimer's disease.
    Lopez OL; Becker JT; Chang YF; Sweet RA; Aizenstein H; Snitz B; Saxton J; McDade E; Kamboh MI; DeKosky ST; Reynolds CF; Klunk WE
    Am J Psychiatry; 2013 Sep; 170(9):1051-8. PubMed ID: 23896958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antipsychotic use in dementia: the relationship between neuropsychiatric symptom profiles and adverse outcomes.
    Mueller C; John C; Perera G; Aarsland D; Ballard C; Stewart R
    Eur J Epidemiol; 2021 Jan; 36(1):89-101. PubMed ID: 32415541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discontinuation of risperidone in Alzheimer's disease.
    Ling SM; Bonner AF; McMullen TL
    N Engl J Med; 2013 Jan; 368(2):187. PubMed ID: 23301740
    [No Abstract]   [Full Text] [Related]  

  • 17. Discontinuation of risperidone in Alzheimer's disease.
    Power GA
    N Engl J Med; 2013 Jan; 368(2):186-7. PubMed ID: 23301739
    [No Abstract]   [Full Text] [Related]  

  • 18. Discontinuation of risperidone in Alzheimer's disease.
    Gnjidic D; Hilmer SN
    N Engl J Med; 2013 Jan; 368(2):186. PubMed ID: 23301738
    [No Abstract]   [Full Text] [Related]  

  • 19. Discontinuation of risperidone in Alzheimer's disease.
    Devanand DP; Schultz SK; Sultzer DL
    N Engl J Med; 2013 Jan; 368(2):187-8. PubMed ID: 23301737
    [No Abstract]   [Full Text] [Related]  

  • 20. New hope for Alzheimer's dementia as prospects for disease modification fade: symptomatic treatments for agitation and psychosis.
    Stahl SM
    CNS Spectr; 2018 Oct; 23(5):291-297. PubMed ID: 30382934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.